SZsendsCOVID19vaccinetoIndonesia
Admin - admin
于2022年04月19日发表
From: Shenzhen Daily
Updated: 2021-11-22 09:11
A chartered flight carried more than 4 million doses of the COVID-19 vaccine produced by Shenzhen Kangtai Biological Products Co. Ltd. (BioKangtai) to Indonesia on Friday.
The vaccine doses weighed some 15 tons, the Shenzhen airport said.
This was the first adenovirus vector COVID-19 vaccine shipment overseas via chartered flight from the Shenzhen airport. The flight was operated by My Indo Airlines, an Indonesian all-cargo carrier which opened a route between Shenzhen, Singapore and Jakarta earlier.
Including the first batch, BioKangtai plans to send 8.4 million doses of the Kangtai adenovirus vector COVID-19 vaccine, branded as KconecaVac, to Indonesia this November, Zhang Qian, general manager of BioKangtai’s international affairs department, said in a video interview with local media Friday.
BioKangtai started to manufacture the adenovirus vector COVID-19 vaccine in February 2021.
On Oct. 31, the Indonesian National Agency of Drug and Food Control granted the Emergency Use Authorization for COVID-19 Vaccine KconecaVac manufactured by BioKangtai. This was China’s second adenovirus vector COVID-19 vaccine approved for emergency use overseas.
Taking this export as a starting point, BioKangtai will accelerate the supply of its COVID-19 vaccine to more countries and increase its accessibility globally, especially in developing countries, according to Zhang.
During the whole transportation, the vaccine doses were stored at temperatures ranging between 2 and 8 degrees Celsius.
“The Shenzhen airport’s flight network and professional services will help BioKangtai to contribute Shenzhen’s strength in the global fight against COVID-19 and more BioKangtai vaccine will be shipped through the airport,” Zhang said.
According to public information, the COVID-19 vaccine BioKangtai independently developed and produced was approved for emergency use in China in May this year, making BioKangtai the only company in the world that possesses two types of COVID-19 vaccines approved for emergency use authorization.
